Mga Batayang Estadistika
| LEI | 213800GFBCNY1ZFST722 |
| CIK | 899460 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MannKind Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
FIRST AMENDMENT LICENSE AND COLLABORATION AGREEMENT CONFIDENTIAL CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2025 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| August 25, 2025 |
MannKind Corporate Announcement EX-99.(a)(5)(E) Exhibit (a)(5)(E) MannKind Corporate Announcement LINKEDIN August 25, 2025 MannKind has announced the signing of a definitive merger agreement to acquire scPharmaceuticals. This acquisition marks MannKind’s strategic expansion into cardiorenal medicine, establishing the company’s cardiometabolic business alongside its orphan lung division. You can read more information about this e |
|
| August 25, 2025 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases • Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unm |
|
| August 25, 2025 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among MANNKIND CORPORATION, SEACOAST MERGER SUB, INC. and scPHARMACEUTICALS INC. Dated as of August 24, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Certain Interpretations 17 ARTICLE II THE OFFER 18 2.1 The Offer 18 2.2 Company Actions 21 ARTICLE III THE MERGER 22 3.1 Merger of Purchaser |
|
| August 25, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 scPharmaceuticals Inc. (Name of Subject Company (Issuer)) Seacoast Merger Sub, Inc. (Offeror) an indirect wholly owned subsidiary of MannKind Corporation (Parent of Offeror) Common Stock, $0.0001 Par Value (Titl |
|
| August 25, 2025 |
EX-99.(a)(5)(C) Exhibit (a)(5)(C) Mannitarians, On behalf of the board of directors and leadership team I am excited to share a major milestone in MannKind’s journey: today we have entered into a definitive merger agreement to acquire scPharmaceuticals, a company with deep expertise in cardiorenal care and a shared commitment to patient-centric innovation. This acquisition marks a pivotal moment f |
|
| August 25, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 scPharmaceuticals Inc. (Name of Subject Company (Issuer)) Seacoast Merger Sub, Inc. (Offeror) an indirect wholly owned subsidiary of MannKind Corporation (Parent of Offeror) Common Stock, $0.0001 Par Value (Titl |
|
| August 25, 2025 |
EX-99.2 MannKind Acquisition of scPharmaceuticals August 25, 2025 Exhibit 99.2 Cautionary Statement Additional Information about the Transaction and Where to Find It The tender offer described in this presentation (the Offer) has not yet commenced, and this presentation is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of sc |
|
| August 25, 2025 |
EX-99.(a)(5)(D) Exhibit (a)(5)(D) Dear scPharmaceuticals Team, As we announce our intent to join forces, I want to take a moment to acknowledge the significance of this moment and share a few thoughts directly with you. At MannKind, we are driven by a shared aspiration to improve the lives of people with serious unmet medical needs. As we look ahead, we see tremendous opportunity in bringing our t |
|
| August 25, 2025 |
EX-10.1 Exhibit 10.1 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of August 24, 2025, by and among MannKind Corporation, a Delaware corporation (“Parent”), Seacoast Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and [] (“Stockholder”). RECITALS A. Stockholder is a holder of record and th |
|
| August 25, 2025 |
AMENDMENT NO. 1 TO LOAN AGREEMENT AND SECURITY AGREEMENT EX-10.2 Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO LOAN AGREEMENT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO LOAN AGREEMENT (this “Amendment”) is dated as of August 24, 2025 and is entered into by and among MANNKIND CORPORATION, a Delaware corporation (the “Borrower”), the Amendment No. 1 Incremental Term Lenders (as defined below), the other Lenders party hereto, and WILMINGTON TRUST, |
|
| August 25, 2025 |
MannKind Corporation Investor Call EX-99.(a)(5)(F) Exhibit (a)(5)(F) MannKind Corporation Investor Call Operator: Good morning and welcome to the MannKind Corporation’s call to discuss its acquisition of scPharmaceuticals. The call will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and will be available for approximately 90 days. During the course of this call, management ma |
|
| August 25, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2025 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other Jurisdiction of Incorporation) (Commi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| August 6, 2025 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference call today at 9:00 am ET • 2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 • YTD 2025 revenues of $154.9M, +12% v. YTD 2024 • Advanced pipeline: o Submitted sBLA for Afrezza® in pediatric population o MNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of schedule o MNKD-201: |
|
| August 6, 2025 |
Exhibit 10.1 May 14, 2025 Re: Transition and Separation Agreement Dear Burkhard Blank: This letter sets forth the terms of the transition and separation agreement (the “Agreement”) that MannKind Corporation (the “Company”) is offering to you. 1. Separation Date. As we have discussed, due to our corporate transition your employment termination date (the “Separation Date”) will be August 1, 2025, or |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 6, 2025 |
Exhibit 10.2 LOAN AGREEMENT Dated as of August 6, 2025 between MANNKIND CORPORATION, (as Borrower), Certain Subsidiaries of Borrower from time to time party hereto, (as other Credit Parties), WILMINGTON TRUST, NATIONAL ASSOCIATION, (as Agent), BLACKSTONE ALTERNATIVE CREDIT ADVISORS LP, (as Blackstone Representative and Lead Arranger), and the Lenders from time to time party hereto |US-DOCS\1619077 |
|
| May 19, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 9, 2025 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
Exhibit 10.2 FIFTH AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”), having a principal place of business at One Casper Street, Danbury, Connecticut 06810, and United Therapeutics Corporation, a Delaware public benefit corporation (“United Therapeutics”), having a principal place |
|
| May 8, 2025 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference call to provide corporate updates today at 9:00 am ET • 1Q 2025 revenues of $78M, +18% v. 1Q 2024 • 1Q 2025 net income of $13M, + 24% v. 1Q 2024 • 1Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024 • Advanced pipeline: • Expect to submit sBLA for Afrezza® in pediatric patients i |
|
| May 8, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.1 Non-employee Director Compensation Adopted November 17, 2017 Modified November 14, 2018 Modified August 2, 2024 Element Amount Annual Cash Retainer $50,000 (cash) In lieu of cash, a director can elect to receive a RSU valued at $50,000 on the basis of the 20-day trailing average closing price as of the trading day immediately preceding the date of the annual meeting Annual Equity Gran |
|
| May 8, 2025 |
Exhibit 10.3 SIXTH AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”), having a principal place of business at One Casper Street, Danbury, Connecticut 06810, and United Therapeutics Corporation, a Delaware public benefit corporation (“United Therapeutics”), having a principal place |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporati |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| February 26, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.11 MANNKIND CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MANNKIND CORPORATION, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the |
|
| February 26, 2025 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference call to provide corporate updates today at 4:30 pm ET • 2024 revenues of $286M, + 43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 2023 • 2024 net income of $28M; Non-GAAP net income of $68M • 4Q 2024 net income of $7M; Non-GAAP net income of $23M • Reduced debt pr |
|
| February 26, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) MannKind Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common stock, par value $0. |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 26, 2025 |
Power of Attorney (included on signature page). As Filed with the Securities and Exchange Commission on February 26, 2025 Registration No. |
|
| February 26, 2025 |
Exhibit 19.1 POLICY AGAINST TRADING ON THE BASIS OF INSIDE INFORMATION December 2019 PERSONS COVERED The policies and procedures outlined herein shall apply to all directors, officers, employees and consultants of MannKind Corporation (the “Company”) and its subsidiaries. POLICIES AND PROCEDURES During the course of your directorship, employment or consultancy with the Company or a subsidiary ther |
|
| February 26, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.13 MANNKIND CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MANNKIND CORPORATION, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing u |
|
| February 26, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.12 MANNKIND CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MANNKIND CORPORATION, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing u |
|
| February 26, 2025 |
Exhibit 1.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. MannKind Corporation Shares of Common Stock (par value $0.01 per share) Amended and Restated Controlled Equity OfferingSM Sales Agreement February 26, 2025 Cantor Fitzgerald & |
|
| February 26, 2025 |
Exhibit 4.8 MannKind Corporation, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exa |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 02, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 17, 2024 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 7, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 7, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corpo |
|
| November 7, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 7, 2024 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call to Begin Today at 4:30 p.m. (ET) • 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023 • YTD 2024 Total revenues of $209M; +49% vs. YTD 2023 • YTD 2024 Net income of $20 million; Non-GAAP net income of $45 million • Orphan lung disease studies proceeding as planned o MNKD-101 Ph |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 13, 2024 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2024 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 9:00 a.m. (ET) • 2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023 • YTD 2024 Total revenues of $139M; +55% vs. YTD 2023 • YTD 2024 Net income of $9 million; Non-GAAP net income of $29 million • Advances two orphan lung programs to human studies o M |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporati |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2024 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 • 1Q 2024 Net income of $11M; Non-GAAP net income of $15M • $304M of cash and cash equivalents and investments at March 31, 2024 • In early April, repaid Midcap senior-secured debt an |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 26, 2024 |
Offer Letter, dated March 25, 2024, between MannKind Corporation and Chris Prentiss. Exhibit 10.1 March 25, 2024 Christopher Prentiss Dear Christopher Prentiss, Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position of Chief Financial Officer. In this position, you will report directly to Michael Castagna, CEO. Your position wil |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 25, 2024 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 27, 2024 |
Exhibit 97 MANNKIND CORPORATION Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) and the Compensation Committee (the “Compensation Committee”) of the Board of MannKind Corporation, a Delaware corporation (the “Company”), have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment P |
|
| February 27, 2024 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General Our authorized capital stock consists of 800,000,000 shares of common stock, $0.01 par value, and 10,000,000 shares of preferred stock, $0.01 par value. All of our authorized preferred stock is undesignated. Our board of directors is authorized, without stockholder approval except as required by the listing standards of The Nasdaq Stock Market LLC, t |
|
| February 27, 2024 |
Offer Letter, dated May 16, 2023, by and between MannKind Corporation and Sanjay Singh. Exhibit 10.4 Offer Letter - Sanjay Singh September 19, 2022 Sanjay Singh Dear Sanjay Singh, Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position of Executive Vice President, Technical Operations, Member of Executive Leadership Team. In this po |
|
| February 27, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| February 27, 2024 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022 • 4Q 2023 Total revenues of $58M; +62% vs. 2022 • 4Q 2023 Net income of $1M; Non-GAAP net income of $7M • $302M of cash and cash equivalents and investments at December 31, |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exa |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 27, 2024 |
Offer Letter, dated September 19, 2022, by and between MannKind Corporation and Burkhard Blank. Exhibit 10.6 Offer Letter - Burkhard Blank May 16, 2023 Burkhard Blank Dear Burkhard, Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position of Executive Vice President, Research & Development/Chief Medical Officer. In this position, you will re |
|
| February 13, 2024 |
MNKD / MannKind Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: MannKind Corp Title of Class of Securities: Common Stock CUSIP Number: 56400P706 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 2, 2024 |
Exhibit 99.1 PURCHASE AND SALE AGREEMENT dated as of December 27, 2023 between MANNKIND CORPORATION and SAGARD HEALTHCARE PARTNERS FUNDING BORROWER SPE 2, LP Table of Contents Page ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 11 ARTICLE II PURCHASE AND SALE OF THE PURCHASED ASSETS 12 Section 2.1 Purchase and Sale; Purchase Price |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizati |
|
| December 27, 2023 |
EX-99.1 Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SEVENTH AMENDMENT TO SUPPLY AGREEMENT This seventh amendment (“Seventh Amendment”) to the Supply Agreement by and between MannKind Corporation (“MannKind”) and Amphas |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizati |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2023 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 • 3Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 2022 • 3Q 2023 Net income of $2M; Non-GAAP net income of $4M • 3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q 2022 • 3Q 2023 Endocrine BU net revenues of $18M; A |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corpo |
|
| August 23, 2023 |
EX-99.2 Exhibit 99.2 MANNKIND CORPORATION 2004 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS MARCH 23, 2004 APPROVED BY STOCKHOLDERS MARCH 23, 2004 AMENDED BY THE BOARD OF DIRECTORS FEBRUARY 21, 2018 AMENDED PLAN APPROVED BY THE STOCKHOLDERS MAY 16, 2018 AMENDED BY THE BOARD OF DIRECTORS MARCH 17, 2023 AMENDED PLAN APPROVED BY THE STOCKHOLDERS MAY 25, 2023 1. PURPOSE. (a) The purp |
|
| August 23, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MannKind Corporation (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity MannKind Corporation 2018 Equity Incentive Plan Common Stock, $0. |
|
| August 23, 2023 |
As filed with the Securities and Exchange Commission on August 23, 2023 Form S-8 As filed with the Securities and Exchange Commission on August 23, 2023 Registration No. |
|
| August 23, 2023 |
EX-99.1 Exhibit 99.1 MANNKIND CORPORATION 2018 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 21, 2018 APPROVED BY THE STOCKHOLDERS: MAY 16, 2018 AMENDED BY THE BOARD OF DIRECTORS: MARCH 23, 2020 AMENDMENT APPROVED BY THE STOCKHOLDERS: MAY 21, 2020 AMENDED BY THE BOARD OF DIRECTORS: MARCH 17, 2023 AMENDMENT APPROVED BY THE STOCKHOLDERS: MAY 25, 2023 1. GENERAL. (a) Successor to |
|
| August 7, 2023 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 SECOND QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 • 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 2023 • 2Q 2023 Endocrine Business Unit net revenues of $18M; Afrezza net revenues +27% vs. 2Q 2022 • 2Q 2023 Income from operations of $2M; Non-GAAP income from operat |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| August 7, 2023 |
Exhibit 10.1 MannKind Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: February 21, 2018 Approved by the Stockholders: May 16, 2018 Amended by the Board of Directors: March 23, 2020 Amendment Approved by the Stockholders: May 21, 2020 Amended by the Board of Directors: March 17, 2023 Amendment Approved by the Stockholders: [May 25, 2023] 1. General. (a) Successor to and Co |
|
| August 7, 2023 |
Exhibit 10.2 MannKind Corporation 2004 Employee Stock Purchase Plan Adopted by the Board of Directors March 23, 2004 Approved by Stockholders March 23, 2004 Amended by the Board of Directors February 21, 2018 Amended Plan Approved by the Stockholders May 16, 2018 Amended by the Board of Directors March 17, 2023 Amended Plan Approved by the Stockholders May 25, 2023 1. Purpose. (a) The purpose of t |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organization) ( |
|
| May 30, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MANNKIND CORPORATION MANNKIND CORPORATION, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: FIRST: The original name of the Corporation was Pharmaceutical Discovery Corporation and the date of f |
|
| May 10, 2023 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated with Tyvaso DPI of $23 million • 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million • $167 million of Cash, Cash Equivalents and Investments at March 31, 2023 DANBUR |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (AMENDMENT NO. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporatio |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporati |
|
| May 9, 2023 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated with Tyvaso DPI of $23 million • 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million • $167 million of Cash, Cash Equivalents and Investments at March 31, 2023 DANBUR |
|
| April 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| April 11, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Conf |
|
| March 27, 2023 |
LAUREN SABELLA JOINS MANNKIND AS EXECUTIVE VICE PRESIDENT, CHIEF OPERATING OFFICER EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE LAUREN SABELLA JOINS MANNKIND AS EXECUTIVE VICE PRESIDENT, CHIEF OPERATING OFFICER DANBURY, Conn., March 27, 2023 (Globe Newswire) – MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has j |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 21, 2023 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 27, 2023 |
EX-10.1 Exhibit 10.1 March 21, 2023 Lauren Sabella Dear Lauren, Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position of Executive Vice President, Chief Operating Officer. In this position, you will report directly to Michael Castagna, Chief Ex |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exa |
|
| February 23, 2023 |
Exhibit 10.49 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind” |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 23, 2023 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 23, 2023 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 2022 Total Revenues of $100 million; +32% vs. 2021 • 2022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million • 4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021 • $173 million of Cash and Cash Equivalents and Investments |
|
| February 23, 2023 |
Exhibit 10.42 Execution Version AMENDMENT NO. 8 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 8 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 3rd day of November, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QRUMPHARMA, INC., a Delaware corporation (“QP”), TECHNOSPHE |
|
| February 23, 2023 |
Exhibit 10.52 OFFICE LEASE AGREEMENT BY AND BETWEEN RFP LINCOLN 293, LLC AND VALERITAS, INC. DATED : May 10, 2017 TABLE OF CONTENTS PAGE ARTICLE I SUMMARY OF BASIC LEASE PROVISIONS 1 1.1 INTRODUCTION 1 1.2 BASIC DATA 1 1.3 ENUMERATION OF EXHIBITS 4 ARTICLE II DESCRIPTION OF PREMISES AND APPURTENANT RIGHTS 5 2.1 LOCATION OF PREMISES 5 2.2 APPURTENANT RIGHTS AND RESERVATIONS 5 2.3 RIGHT OF FIRST OFF |
|
| February 23, 2023 |
Exhibit 10.53 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the “ Amendment ”) is made as of the 11th day of February 2019 (the “Effective Date ”) by and between BPR 293 EQUITY PARTNERS, LLC , a Massachusetts limited liability company (“Landlord ”), and VALERITAS, INC ., a Delaware corporation (“ Tenant ”). RECITALS A. Pursuant to that certain lease dated as of May 10, 2017 (the “ Origin |
|
| February 23, 2023 |
Exhibit 10.43 Execution Version AMENDMENT NO. 9 AND LIMITED CONSENT TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 9 AND LIMITED CONSENT TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 8th day of November, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QRUMPHARMA, INC., a |
|
| February 23, 2023 |
Exhibit 10.50 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind”) |
|
| February 23, 2023 |
Exhibit 10.51 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. FOURTH AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (“MannKind” |
|
| February 9, 2023 |
MNKD / MannKind Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01359-mannkindcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: MannKind Corp. Title of Class of Securities: Common Stock CUSIP Number: 56400P706 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the ru |
|
| November 8, 2022 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 9:00 a.m. (ET) • 3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021 • 3Q 2022 Royalties from Tyvaso DPI of $6.2 million • 3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. November 8, 2022 (Globe Newswire) — Man |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 8, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corpo |
|
| November 8, 2022 |
Exhibit 10.1 AMENDMENT NO. 10 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 10 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 29th day of August, 2022, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QrumPharma, Inc., a Delaware corporation (“QP”), TECHNOSPHERE INTERNATIONAL, |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 26, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 23, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2022 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2022 SECOND QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) ? Tyvaso DPITM approved by the FDA in May representing the second FDA-approved product using the Technosphere? inhalation platform ? V-Go? acquired May 31; $2.1 million Net Revenue recognized for June ? 2Q 2022 Commercial Products Net Revenue of $12.7 million; +28% vs. 2 |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 9, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| May 25, 2022 |
MANNKIND’S TECHNOSPHERE® INHALATION PLATFORM UTILIZED IN FDA-APPROVED TYVASO DPI™ EX-99.1 2 mnkd-ex99126.htm EX-99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE MANNKIND’S TECHNOSPHERE® INHALATION PLATFORM UTILIZED IN FDA-APPROVED TYVASO DPI™ • Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technology • First approval of a dry powder inhaled treatment for PAH and PH-ILD • Manufacturing of Tyvaso DPI for United Therapeutics underway at |
|
| May 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 24, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 17, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 10, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 5, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO OFFICE LEASE This THIRD AMENDMENT TO OFFICE LEASE (this "Amendment") is entered into as of April 8, 2022 (the ?Effective Date?), by and between RUSSELL RANCH ROAD II LLC, a Delaware limited liability company ("Landlord"), and MANNKIND CORPORATION, a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are parties to that certain Office Lease dated as of M |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporati |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 5, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 5, 2022 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2022 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) ? 1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 2021 ? 1Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021 ? $233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022 ? Tyvaso DPI PDUFA date May 2022 DANBURY, Conn. and WESTLAKE VILL |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? |
|
| March 30, 2022 |
DEFA14A 1 mnkd-defa14a20220510.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate |
|
| February 24, 2022 |
EX-4.8 2 d277875dex48.htm EX-4.8 Exhibit 4.8 MannKind Corporation, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securiti |
|
| February 24, 2022 |
Power of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.11 MANNKIND CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MANNKIND CORPORATION, a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the |
|
| February 24, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.12 MANNKIND CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MANNKIND CORPORATION, a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing u |
|
| February 24, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MannKind Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 24, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 24, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.13 MANNKIND CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MANNKIND CORPORATION, a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing u |
|
| February 24, 2022 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2021 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) ? 2021 Total Revenues of $75.4 million; +16% vs. 2020 ? 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020 ? $260.7 million of Cash, Cash Equivalents and Investments at December 31, 2021 ? Commenced clofazimine Phase 1 clinical trial in 1Q 2022 |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exa |
|
| February 10, 2022 |
MNKD / MannKind Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: MannKind Corp. Title of Class of Securities: Common Stock CUSIP Number: 56400P706 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 18, 2022 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 27, 2021 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 9, 2021 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corpo |
|
| November 9, 2021 |
EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2021 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) ? 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 2020 ? 3Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020 ? $181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021 ? Sale-Leaseback of Danbury manufacturing facility closed November |
|
| November 9, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This amendment is effective the last date signed by a party, between MannKind Corporation, a Delaware corporation (?MannKind?), |
|
| November 9, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT Between MANNKIND CORPORATION ?Seller? and 1 CASPER, LLC ?Buyer? with Escrow Instructions for FIRST AMERICAN TITLE INSURANCE COMPANY ?Escrow Holder |
|
| November 9, 2021 |
Exhibit10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT This commercial supply agreement (this ?Agreement?) is entered into as of August 12, 2021 (the ?Effective Date?) between MannKind Corporation, a De |
|
| October 18, 2021 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizatio |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizat |
|
| August 16, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 13, 2021 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 16, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorpora |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 11, 2021 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 11, 2021 |
EXHIBIT 99.1 MannKind Corporation Reports 2021 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET ? 2Q 2021 Total Revenues of $23.3 million; +54% vs. 2Q 2020 ? 2Q 2021 Afrezza Net Revenue of $10.0 million; +43% vs. 2Q 2020 ? $201.4 million of Cash, Cash Equivalents and Investments at June 30, 2021 WESTLAKE VILLAGE, Calif., August 11, 2021 (GLOBE NEWSWIRE) - MannKind Corp |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| June 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organization) |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organization) ( |
|
| May 25, 2021 |
SIXTH AMENDMENT TO SUPPLY AGREEMENT Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SIXTH AMENDMENT TO SUPPLY AGREEMENT This sixth amendment (?Sixth Amendment?) to the Supply Agreement by and between MannKind Corporation (?MannKind?) and Amphastar Pharmaceut |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporati |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2021 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 12, 2021 |
EXHIBIT 99.1 MannKind Corporation Reports 2021 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET ? 1Q 2021 Total Revenues of $17.4 million; +7% vs. 1Q 2020 ? Received $230.0 million gross proceeds from 2.5% senior convertible notes ? $278.3 million of Cash, Cash Equivalents and Investments at March 31, 2021 ? Tyvaso DPITM NDA submitted to the FDA by collaboration partner |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 26, 2021 |
AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT Exhibit 99.1 Execution Version AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT (this ?Agreement?) is made as of this 22nd day of April, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (?MannKind?), MANNKIND LLC, a Delaware limited liability company (?MannKind LLC?), QRUMPHARMA, INC., a Delaware corporation (?QP?, and, QP, toget |
|
| April 26, 2021 |
AMENDMENT No. 1 TO CONVERTIBLE PROMISSORY NOTE Exhibit 99.2 Execution Version AMENDMENT No. 1 TO CONVERTIBLE PROMISSORY NOTE THIS AMENDMENT No. 1 TO CONVERTIBLE PROMISSORY NOTE (this ?Amendment?), dated as of April 22, 2021, amends that certain Convertible Promissory Note issued by MannKind Corporation, a Delaware corporation (the ?Borrower?) to Mann Group, LLC (the ?Lender?), dated as of August 6, 2019, in the original principal amount of $35 |
|
| April 26, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 7, 2021 |
DEF 14A 1 nc10020142x1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate bo |
|
| April 7, 2021 |
DEFA14A 1 nc10020142x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate b |
|
| March 5, 2021 |
AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT EX-99.1 Exhibit 99.1 Execution Version AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 1st day of March, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QRUMPHARMA, INC., a Delaware corporation (“QP”, and, QP |
|
| March 5, 2021 |
MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes Exhibit 99.2 MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes March 1, 2021 WESTLAKE VILLAGE, Calif., March 01, 2021 (GLOBE NEWSWIRE) ? MannKind Corporation (NASDAQ:MNKD) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the ?notes?) in a priv |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission File |
|
| March 5, 2021 |
MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering Exhibit 99.3 MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering March 2, 2021 WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) ? MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the ?notes?) in a private placement (the ?offering?) to qualified instituti |
|
| March 5, 2021 |
Exhibit 4.1 MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 4, 2021 2.50% Convertible Senior Notes due 2026 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01 . Definitions 1 Section 1.02 . References to Interest 15 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01 . Designation and Amount 15 Section 2.02 |
|
| February 25, 2021 |
Exhibit 10.4 May 7th, 2020 Dear Alejandro Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position of Executive Vice President, Chief Commercial Officer. In this position you will report directly to Michael Castagna, Chief Executive Officer. We wi |
|
| February 25, 2021 |
Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE MANNKIND CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO MANNKIND CORPORATION IF PUBLICLY DISCLOSED. 28903 North Avenue Paine, Valencia, California 91355 USA 61 South Paramus Road, Paramus, New Jersey 07652 USA One Caspe |
|
| February 25, 2021 |
EXHIBIT 99.1 MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 9:00 AM ET • 4Q 2020 Afrezza Net Revenue of $10.1 million; +30% vs. 4Q 2019 o Sequential Quarter Growth +38% vs. 3Q 2020 • 2020 Total Revenues of $65.1 million o 2020 Afrezza Net Revenue of $32.3 million; +28% vs. 2019 o 2020 Afrezza Gross Profit $17.2 million; 53% Gross |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exa |
|
| February 25, 2021 |
EX-4.3 2 mnkd-ex4310.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF COMMON STOCK General Our authorized capital stock consists of 400,000,000 shares of common stock, $0.01 par value, and 10,000,000 shares of preferred stock, $0.01 par value. All of our authorized preferred stock is undesignated. Our board of directors is authorized, without stockholder approval except as required by the listing standards o |
|
| February 25, 2021 |
EX-10.5 4 mnkd-ex105263.htm EX-10.5 Exhibit 10.5 August 11, 2003 Dear Joe: I am pleased to confirm MannKind’s offer to you for full-time employment in the position of Senior Director, Pharmaceutical Manufacturing, effective September 1, 2003. In this position, you will report directly to me. You will be paid on a bi-weekly basis, along with our regular payroll schedule, equating to an annualized a |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 25, 2021 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: MannKind Corp. Title of Class of Securities: Common Stock CUSIP Number: 56400P706 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d |
|
| December 30, 2020 |
EX-99.1 Exhibit 99.1 OMNIBUS JOINDER AND AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT This OMNIBUS JOINDER AND AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT (this “Agreement”) is made as of this 29th day of December, 2020, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a De |
|
| December 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission F |
|
| December 7, 2020 |
EX-99.1 Exhibit 99.1 MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc. Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product WESTLAKE VILLAGE, Calif., December 7, 2020 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) today announced that it has acquired QrumPharma, Inc., a privately held pharma |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission F |
|
| December 7, 2020 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION STOCK PURCHASE AGREEMENT by and among MannKind Corporation; QrumPharma, Inc.; the Sellers named herein; and SHR Services LLC, as the Securityholders’ Representative Dated as of December 7, 2020 TABLE OF CONTENTS PAGE SECTION 1. DESCRIPTION OF TRANSACTION 1 1.1 Certain Definitions 1 1.2 Sale and Purchase of Shares; Closing 20 1.3 Consideration for Shares 21 1. |
|
| December 7, 2020 |
EX-4.1 Exhibit 4.1 EXECUTION VERSION AMENDMENT NO. 4 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 7th day of December, 2020, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), as a Borrower, MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), as a Borrower, MIDCAP FINANCIAL TRUST, as |
|
| December 1, 2020 |
AMENDMENT NO. 3 CREDIT AND SECURITY AGREEMENT EX-99.1 Exhibit 99.1 Execution Version AMENDMENT NO. 3 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 30th day of November, 2020, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), as a Borrower, MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), as a Borrower, MIDCAP FINANCIAL TRUST, |
|
| December 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission |
|
| November 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation) (Commission |
|
| November 4, 2020 |
EXHIBIT 99.1 MannKind Corporation Reports 2020 Third Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million; +27% vs. 3Q 2019 • 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million; +31% vs. 3Q YTD 2019 • Cash and cash equivalents of $52.4 million at September 30, 2020 • On track to complete Treprostinil Technosphere development a |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 4, 2020 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corpo |
|
| August 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organization) |
|
| August 25, 2020 |
AMENDMENT NO. 2 CREDIT AND SECURITY AGREEMENT EX-99.1 Exhibit 99.1 Execution Version AMENDMENT NO. 2 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 21st day of August, 2020, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), as a Borrower, MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), as a Borrower, MIDCAP FINANCIAL TRUST, as |
|
| August 25, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 21, 2020 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 7, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 7, 2020 Registration No. |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2020 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| August 5, 2020 |
Exhibit 10.1 MannKind Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: February 21, 2018 Approved by the Stockholders: May 16, 2018 Amended by the Board of Directors: March 23, 2020 Amendment Approved by the Stockholders: May 21, 2020 1. General. (a)Successor to and Continuation of Prior Plans. The Plan is intended as the successor to and continuation of the MannKind Corpo |
|
| August 5, 2020 |
EXHIBIT 99.1 MannKind Corporation Reports 2020 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 2Q 2020 Afrezza Net Revenue of $7.0 million; +15% vs. 2Q 2019 • 1H 2020 Afrezza Net Revenue of $15.0 million; +35% vs. 1H 2019 • Cash and cash equivalents of $63.2 million at June 30, 2020 • Non-GAAP cash used in operating activities decreased by 37% vs. 1H 2019 • Chief Co |
|
| May 27, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MANNKIND CORPORATION (A DELAWARE CORPORATION) AMENDED AND RESTATED BYLAWS OF MANNKIND CORPORATION (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of MannKind Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The |
|
| May 27, 2020 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MANNKIND CORPORATION MANNKIND CORPORATION, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: FIRST: The original name of the Corporation was Pharmaceutical Discovery Corporation and the date of f |
|
| May 27, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizatio |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2020 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporati |
|
| May 6, 2020 |
EXHIBIT 99.1 MannKind Corporation Reports 2020 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 1Q 2020 Afrezza Net Revenue of $8.0 million; +58% vs. 1Q 2019 • 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 • Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif., May 6, 2020 (GLOBE NEW |
|
| April 15, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizat |
|
| April 15, 2020 |
EX-99.1 Exhibit 99.1 NOTE Date 4/9/2020 Note Amount $4,872,860 Borrower MannKind Corporation Lender JPMorgan Chase Bank, N.A. 1. PROMISE TO PAY. Borrower promises to pay to the order of Lender the Note Amount, plus interest on the unpaid principal balance at the Note Rate, and all other amounts required by this Note. 2. DEFINITIONS. “CARES Act” means the Coronavirus Aid, Relief, and Economic Secur |
|
| April 10, 2020 |
MNKD / MannKind Corp. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Conf |
|
| April 10, 2020 |
MNKD / MannKind Corp. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| April 1, 2020 |
MNKD / MannKind Corp. PRE 14A - - PRE 14A PRE 14A 1 nc10009819x1pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate bo |
|
| March 24, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2020 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizat |
|
| March 24, 2020 |
Jennifer Grancio Appointed to MannKind Board of Directors EX-99.1 EXHIBIT 99.1 Jennifer Grancio Appointed to MannKind Board of Directors WESTLAKE VILLAGE, Calif., March 24, 2020 — MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Ms. Grancio brings to MannKind over twenty years of fina |
|
| February 25, 2020 |
EXHIBIT 99.1 MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 9:00 AM ET • 2019 Total Revenue of $63.0 million o 2019 Afrezza Net Revenue of $25.3 million; +46% vs. 2018 o 2019 Collaborations and Services Revenue of $37.7 million; +257% vs. 2018 • 4Q 2019 Total Revenue of $16.0 million o 4Q 2019 Afrezza Net Revenue of $7.8 million; |
|
| February 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 25, 2020 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 25, 2020 |
MNKD / MannKind Corp. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exa |
|
| February 25, 2020 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General Our authorized capital stock consists of 280,000,000 shares of common stock, $0.01 par value, and 10,000,000 shares of preferred stock, $0.01 par value. All of our authorized preferred stock is undesignated. Our board of directors is authorized, without stockholder approval except as required by the listing standards of The Nasdaq Stock Market LLC, t |
|
| February 10, 2020 |
MNKD / MannKind Corp. / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 56400P706 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* MannKind Corporation (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 56400P706 (CUSIP Number) |
|
| December 23, 2019 |
EX-4.1 2 d839460dex41.htm EX-4.1 Exhibit 4.1 AMENDMENT TO COMMON STOCK PURCHASE WARRANT This Amendment to Common Stock Purchase Warrant (this “Amendment”) is entered into between MannKind Corporation (the “Company”) and CVI Investments, Inc. (“Holder”) as of December 22, 2019 and amends the terms of that certain Common Stock Purchase Warrant issued to the Holder by the Company on December 26, 2018 |
|
| December 23, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organi |
|
| December 18, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organi |
|
| December 18, 2019 |
AMENDMENT NO. 1 CREDIT AND SECURITY AGREEMENT EX-99.1 Exhibit 99.1 Execution Version AMENDMENT NO. 1 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 18th day of December, 2019, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), as a Borrower, MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), as a Borrower, MIDCAP FINANCIAL TRUST, |
|
| November 21, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organi |
|
| November 21, 2019 |
MannKind Appoints Tony Hooper to Its Board of Directors EX-99.1 Exhibit 99.1 MannKind Appoints Tony Hooper to Its Board of Directors WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020. Mr. Hooper will also serve as a member of the Audit Committee of the Board. Mr. Hooper brings 35 years of experience in the pharmace |
|
| November 8, 2019 |
MNKD / MannKind Corp. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corpo |
|
| November 6, 2019 |
EXHIBIT 99.1 MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results Conference Call to Begin Today at 9:00 AM ET • 3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018 o 3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018 ▪ Afrezza sold to our marketing partner in Brazil for launch was $0.7 million o 3Q 2019 Collaborations and Services Revenue was $8.2 milli |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 mnkd-8k20191106.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 6, 2019 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of In |
|
| August 7, 2019 |
EX-4.6 Exhibit 4.6 EXECUTION VERSION THE SECURITY REPRESENTED BY THIS CERTIFICATE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS SECURITY MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATI |
|
| August 7, 2019 |
EX-99.3 10 d757696dex993.htm EX-99.3 Exhibit 99.3 Execution Version EXCHANGE AGREEMENT The Mann Group LLC (the “Holder”), enters into this Exchange Agreement (this “Agreement”) with MannKind Corporation (the “Company”) on August 5, 2019 whereby the Holder will exchange that certain Amended and Restated Promissory Note, dated as of March 11, 2018, issued by the Company to the Holder in a principal |
|
| August 7, 2019 |
EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LA |
|
| August 7, 2019 |
EX-99.2 Exhibit 99.2 Execution Version EXCHANGE AGREEMENT Bruce Fund, Inc. (the “Undersigned”), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (“Accounts”) for whom the Undersigned holds contractual and investment authority (each Account, as well as the Undersigned if it is exchanging Notes (as defined below) hereunder, a “Holder”), enters into this Exchange Agreement |
|
| August 7, 2019 |
EX-4.4 Exhibit 4.4 THE SECURITY REPRESENTED BY THIS CERTIFICATE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION, PURSU |
|
| August 7, 2019 |
EX-4.5 5 d757696dex45.htm EX-4.5 Exhibit 4.5 THE SECURITY REPRESENTED BY THIS CERTIFICATE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, |
|
| August 7, 2019 |
EX-99.1 Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Execution Version CREDIT AND SECURITY AGREEMENT dated as of August 6, 2019 by and among MANNKIND CORPORATION, MANNKIND LLC, each as a Borrower and any additional borrower that here |
|
| August 7, 2019 |
EX-99.4 11 d757696dex994.htm EX-99.4 Exhibit 99.4 Execution Version EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) dated as of August 6, 2019 (the “Closing Date”), is by and among MannKind Corporation, a Delaware corporation (the “Borrower”), MannKind LLC, a Delaware limited liability company (“Guarantor” and together with the Borrower, collectively, the “Obligors”), Deerfield Priva |
|
| August 7, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizat |
|
| August 7, 2019 |
EX-4.3 Exhibit 4.3 MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 6, 2019 5.75% Convertible Senior Subordinated Exchange Notes Due 2024 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS; INTERPRETATIONS SECTION 1.01. Definitions 1 SECTION 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES SECTION 2 |
|
| August 7, 2019 |
FIFTH AMENDMENT TO SUPPLY AGREEMENT EX-99.5 Exhibit 99.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. FIFTH AMENDMENT TO SUPPLY AGREEMENT This fifth amendment (Fifth Amendment) to the Supply Agreement by and between MannKind Corporation (MannKind) and Amphastar Pharmaceuticals, |
|
| August 7, 2019 |
EX-4.7 Exhibit 4.7 EXECUTION VERSION THE SECURITY REPRESENTED BY THIS CERTIFICATE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 7, 2019 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 7, 2019 |
EXHIBIT 99.1 MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights Conference Call to Begin Today at 5:00 PM ET • 2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018 o 2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018 o 2Q 2019 Collaboration and Services Revenue was $8.9 million • Afrezza approved in Brazil • Entered into exclusive ma |
|
| August 7, 2019 |
MNKD / MannKind Corp. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporatio |
|
| July 18, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizati |
|
| July 18, 2019 |
EX-99.1 Exhibit 99.1 Execution Version EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) dated as of July 18, 2019, is by and among MannKind Corporation, a Delaware corporation (the “Borrower”), MannKind LLC, a Delaware limited liability company (“Guarantor” and together with the Borrower, collectively, the “Obligors”), Deerfield Private Design Fund II, L.P. (“DPDF”) and Deerfield Priv |
|
| June 19, 2019 |
ELEVENTH AMENDMENT TO FACILITY AGREEMENT EX-99.1 2 d765401dex991.htm EX-99.1 Exhibit 99.1 Execution Version ELEVENTH AMENDMENT TO FACILITY AGREEMENT This ELEVENTH AMENDMENT TO FACILITY AGREEMENT (this “Amendment”) dated as of June 18, 2019, is by and among MannKind Corporation, a Delaware corporation (the “Borrower”), MannKind LLC, a Delaware limited liability company (the “Guarantor,” and together with the Borrower, collectively, the “O |
|
| June 19, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d765401d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorp |
|
| May 16, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2019 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 000-50865 13-3607736 (State or other jurisdiction of incorporation or organizatio |
